Catalyst Wire Dossier Catalyst Wire Dossier

Spiolto Respimat

tiotropium/olodaterol · Boehringer Ingelheim
Drug timelines are a Plus or Pro feature.

6 regulatory and trial events tracked for Spiolto Respimat, covering 2018-10-15 to 2024-03-15. Get the full timeline:

Most recent: Clinical Trial Update: Spiolto® Respimat® (Tiotropium/Olodaterol) Versus Triple Combination Therapy in Everyday Clinical Treatment Practice for Chronic Obstructive Pulmonary Disease (EVELUT®)

See pricing